Form 4: AbbVie Executive Thomas J. Hudson Reports Stock Transaction

SVP, CSO, GLOBAL RESEARCH of AbbVie Inc., Thomas J. Hudson, reports disposition of shares to cover tax obligations.

Summary

• On February 28, 2024, Thomas J. Hudson, SVP, CSO, GLOBAL RESEARCH of AbbVie Inc., reported a transaction involving AbbVie's common stock.
• Hudson disposed of 20,634 shares at a price of $178.99.
• Following the transaction, Hudson directly owns 107,267 shares of AbbVie common stock.

Sentiment

Score: 5

Explanation: This Form 4 filing is a routine disclosure of a stock transaction by an AbbVie executive. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC when corporate insiders, like officers and directors, trade their company's stock. These filings are closely watched by investors seeking insights into management's perspective on the company's value and future prospects.

Comparison to Industry Standards

• Executive stock transactions are a common occurrence in publicly traded companies like AbbVie.
• Similar transactions are regularly reported by executives at comparable pharmaceutical companies such as Johnson & Johnson (JNJ), Pfizer (PFE), and Merck (MRK).
• The size and frequency of these transactions can vary widely based on individual compensation structures, stock option grants, and personal financial planning.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders.
• It provides transparency into executive stock ownership, which can be of interest to shareholders.

Key Dates